Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Treatment Options in Oncology
Published in: Current Treatment Options in Oncology 12/2021

01-12-2021 | Buprenorphine | Palliative and Supportive Care (MP Davis, Section Editor)

Treating Chronic Pain with Buprenorphine—The Practical Guide

Authors: Amy A. Case, Justin Kullgren, Sidra Anwar, Sandra Pedraza, Mellar P. Davis

Published in: Current Treatment Options in Oncology | Issue 12/2021

Login to get access

Opinion statement

Buprenorphine has unique and favorable pharmacological properties that make it useful in a variety of clinical scenarios. It has been recommended to consider buprenorphine first-line opioid for chronic pain, especially in the elderly as it may be associated with less cognitive impairment, falls, sexual dysfunction, and sarcopenia when compared with schedule II opioids. It may be useful in patients with comorbid substance use disorder or non-medical opioid use, as there is less risk of misuse, euphoria and it may improve mood. When used to treat opioid use disorder, the training and waiver was recently waived for licensed practitioners with a DEA and any provider may prescribe buprenorphine. For many reasons outlined in this article, the popularity of using buprenorphine for analgesia continues to grow and a practitioner should consider this as an excellent and safe option for chronic pain.
Literature
1.
Dahlhamer J, et al. Prevalence of chronic pain and high-impact chronic pain among adults - United States, 2016. MMWR Morb Mortal Wkly Rep. 2018;67(36):1001–6.PubMedPubMedCentralCrossRef
2.•
Davis MP, Pasternak G, Behm B. Treating chronic pain: an overview of clinical studies centered on the buprenorphine option. Drugs. 2018;78(12):1211–28. Comprehensive review of the use of buprenorphine for pain.PubMedPubMedCentralCrossRef
3.••
Webster L, et al. Understanding buprenorphine for use in chronic pain: expert opinion. Pain Med. 2020;21(4):714–23. Consensus panel recommendations regarding the use and opioid rotation to buprenorphine for pain.PubMedPubMedCentralCrossRef
4.
5.
Pergolizzi JV Jr. And R.B. Raffa, safety and efficacy of the unique opioid buprenorphine for the treatment of chronic pain. J Pain Res. 2019;12:3299–317.PubMedCrossRef
6.••
7.
Suboxone Sublingual Film Prescribing Information. 2019. Indivior Inc.: North Chesterfield.
8.
Buprenex Prescribing Information. 2019. Indivior Inc.: North Chesterfield.
9.
Subutex Prescribing Information. 2015. Roxane Laboratories, Inc.: Columbus.
10.
Zubsolv Prescribing Information. 2019. Orexo US Inc.: Morristown, NJ.
11.
Butrans Prescribing Information. 2019. Perdue Pharm L.P.: Stamford.
12.
Greenwald M, et al. Buprenorphine duration of action: mu-opioid receptor availability and pharmacokinetic and behavioral indices. Biol Psychiatry. 2007;61(1):101–10.PubMedCrossRef
13.
Elkader A, Sproule B. Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence. Clin Pharmacokinet. 2005;44(7):661–80.PubMedCrossRef
14.
Chang Y, Moody DE. Glucuronidation of buprenorphine and norbuprenorphine by human liver microsomes and UDP-glucuronosyltransferases. Drug Metab Lett. 2009;3(2):101–7.PubMedCrossRef
15.
Cone EJ, et al. The metabolism and excretion of buprenorphine in humans. Drug Metab Dispos. 1984;12(5):577–81.PubMed
16.
Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol. 2008;64(12):1147–61.PubMedCrossRef
17.
Alhaddad H, et al. Respiratory toxicity of buprenorphine results from the blockage of P-glycoprotein-mediated efflux of norbuprenorphine at the blood-brain barrier in mice. Crit Care Med. 2012;40(12):3215–23.PubMedCrossRef
18.
Huang P, et al. Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist. J Pharmacol Exp Ther. 2001;297(2):688–95.PubMed
19.
Ohtani M, et al. Comparative analysis of buprenorphine- and norbuprenorphine-induced analgesic effects based on pharmacokinetic-pharmacodynamic modeling. J Pharmacol Exp Ther. 1995;272(2):505–10.PubMed
20.
Tournier N, et al. Interaction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2). Int J Neuropsychopharmacol. 2010;13(7):905–15.PubMedCrossRef
21.
Boger RH. Renal impairment: a challenge for opioid treatment? The role of buprenorphine. Palliat Med. 2006;20(Suppl 1):s17–23.PubMedCrossRef
22.
Middleton LS, et al. The pharmacodynamic and pharmacokinetic profile of intranasal crushed buprenorphine and buprenorphine/naloxone tablets in opioid abusers. Addiction. 2011;106(8):1460–73.PubMedPubMedCentralCrossRef
23.
Volpe DA, et al. Uniform assessment and ranking of opioid mu receptor binding constants for selected opioid drugs. Regul Toxicol Pharmacol. 2011;59(3):385–90.PubMedCrossRef
24.
Gudin J, Fudin J. A narrative pharmacological review of buprenorphine: a unique opioid for the treatment of chronic pain. Pain Ther. 2020;9(1):41–54.PubMedPubMedCentralCrossRef
25.
Dahan A, et al. Buprenorphine induces ceiling in respiratory depression but not in analgesia. Br J Anaesth. 2006;96(5):627–32.PubMedCrossRef
26.
Raehal KM, Bohn LM. The role of beta-arrestin2 in the severity of antinociceptive tolerance and physical dependence induced by different opioid pain therapeutics. Neuropharmacology. 2011;60(1):58–65.PubMedCrossRef
27.
Raehal KM, Walker JK, Bohn LM. Morphine side effects in beta-arrestin 2 knockout mice. J Pharmacol Exp Ther. 2005;314(3):1195–201.PubMedCrossRef
28.
29.
MacLean KA, et al. Dose-related effects of salvinorin a in humans: dissociative, hallucinogenic, and memory effects. Psychopharmacology. 2013;226(2):381–92.PubMedCrossRef
30.
Pfeiffer A, et al. Psychotomimesis mediated by kappa opiate receptors. Science. 1986;233(4765):774–6.PubMedCrossRef
31.•
Ahmadi J, Jahromi MS, Ehsaei Z. The effectiveness of different singly administered high doses of buprenorphine in reducing suicidal ideation in acutely depressed people with co-morbid opiate dependence: a randomized, double-blind, clinical trial. Trials. 2018;19(1):462. A randomized, double-blind trial that suggests a single high dose of buprenorphine could rapidly treat suicidal ideation.PubMedPubMedCentralCrossRef
32.
33.
Lutfy K, Cowan A. Buprenorphine: a unique drug with complex pharmacology. Curr Neuropharmacol. 2004;2(4):395–402.PubMedCrossRef
34.
Johnson RE, Strain EC, Amass L. Buprenorphine: how to use it right. Drug Alcohol Depend. 2003;70(2 Suppl):S59–77.PubMedCrossRef
35.
Khanna IK, Pillarisetti S. Buprenorphine - an attractive opioid with underutilized potential in treatment of chronic pain. J Pain Res. 2015;8:859–70.PubMedPubMedCentral
36.
Ding Z, Raffa RB. Identification of an additional supraspinal component to the analgesic mechanism of action of buprenorphine. Br J Pharmacol. 2009;157(5):831–43.PubMedPubMedCentralCrossRef
37.
Tejwani GA, Rattan AK, McDonald JS. Role of spinal opioid receptors in the antinociceptive interactions between intrathecal morphine and bupivacaine. Anesth Analg. 1992;74(5):726–34.PubMedCrossRef
38.
Mercadante S, et al. Safety and effectiveness of intravenous morphine for episodic breakthrough pain in patients receiving transdermal buprenorphine. J Pain Symptom Manag. 2006;32(2):175–9.CrossRef
39.
Emery MA, Eitan S. Members of the same pharmacological family are not alike: different opioids, different consequences, hope for the opioid crisis? Prog Neuro-Psychopharmacol Biol Psychiatry. 2019;92:428–49.CrossRef
40.
Lintzeris N, et al. Transferring patients from methadone to buprenorphine: the feasibility and evaluation of practice guidelines. J Addict Med. 2018;12(3):234–40.PubMedPubMedCentralCrossRef
41.
Mannelli P, et al. Buprenorphine-mediated transition from opioid agonist to antagonist treatment: state of the art and new perspectives. Curr Drug Abuse Rev. 2012;5(1):52–63.PubMedPubMedCentralCrossRef
42.
Malinoff HL, Barkin RL, Wilson G. Sublingual buprenorphine is effective in the treatment of chronic pain syndrome. Am J Ther. 2005;12(5):379–84.PubMedCrossRef
43.
Mercadante S, et al. Equipotent doses to switch from high doses of opioids to transdermal buprenorphine. Support Care Cancer. 2009;17(6):715–8.PubMedCrossRef
44.
Mercadante S, et al. Switching from transdermal drugs: an observational "N of 1" study of fentanyl and buprenorphine. J Pain Symptom Manag. 2007;34(5):532–8.CrossRef
45.
Likar R, et al. Comparable analgesic efficacy of transdermal buprenorphine in patients over and under 65 years of age. Clin J Pain. 2008;24(6):536–43.PubMedCrossRef
46.
Lundorff L, et al. Switching from high doses of pure mu-opioid agonists to transdermal buprenorphine in patients with cancer: a feasibility study. J Opioid Manag. 2013;9(4):255–62.PubMedCrossRef
47.
Freye E, et al. Opioid rotation from high-dose morphine to transdermal buprenorphine (Transtec) in chronic pain patients. Pain Pract. 2007;7(2):123–9.PubMedCrossRef
48.
Sittl R, Griessinger N, Likar R. Analgesic efficacy and tolerability of transdermal buprenorphine in patients with inadequately controlled chronic pain related to cancer and other disorders: a multicenter, randomized, double-blind, placebo-controlled trial. Clin Ther. 2003;25(1):150–68.PubMedCrossRef
49.••
Sittl R, Likar R, Nautrup BP. Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study. Clin Ther. 2005;27(2):225–37. Buprenorphine transdermal system was shown to be an effective analgesic against chronic, severe pain in this study population. Patients treated with this new formulation of buprenorphine showed improved duration of sleep and reduced need for additional oral analgesics.PubMedCrossRef
50.
Kornfeld H, Reetz H. Transdermal buprenorphine, opioid rotation to sublingual buprenorphine, and the avoidance of precipitated withdrawal: a review of the literature and demonstration in three chronic pain patients treated with butrans. Am J Ther. 2015;22(3):199–205.PubMedCrossRef
51.
Kornfeld H. Buprenorphine as a safety net for opioid treatment of nonmalignant pain. Arch Intern Med. 2011;171(6):596–7.PubMedCrossRef
52.
Saal D, Lee F. Rapid induction therapy for opioid-use disorder using buprenorphine transdermal patch: a case series. Perm J. 2020;24.
53.
Silverman S, et al. Use of immediate-release opioids as supplemental analgesia during management of moderate-to-severe chronic pain with buprenorphine transdermal system. J Pain Res. 2017;10:1255–63.PubMedPubMedCentralCrossRef
54.
Edge WG, Cooper GM, Morgan M. Analgesic effects of sublingual buprenorphine. Anaesthesia. 1979;34(5):463–7.PubMedCrossRef
55.
Cuschieri RJ, Morran CG, McArdle CS. Comparison of morphine and sublingual buprenorphine following abdominal surgery. Br J Anaesth. 1984;56(8):855–9.PubMedCrossRef
56.
Ellis R, et al. Pain relief after abdominal surgery--a comparison of i.m. morphine, sublingual buprenorphine and self-administered i.v. pethidine. Br J Anaesth. 1982;54(4):421–8.PubMedCrossRef
57.
Daitch J, et al. Conversion of chronic pain patients from full-opioid agonists to sublingual buprenorphine. Pain Phys. 2012;15(3 Suppl):ES59–66.CrossRef
58.
Priestley T, et al. Converting from transdermal to buccal formulations of buprenorphine: a pharmacokinetic meta-model simulation in healthy volunteers. Pain Med. 2018;19(10):1988–96.PubMedCrossRef
59.
Webster L, et al. Evaluation of the tolerability of switching patients on chronic full mu-opioid agonist therapy to buccal buprenorphine. Pain Med. 2016;17(5):899–907.PubMedPubMedCentral
60.•
Hammig R, et al. Use of microdoses for induction of buprenorphine treatment with overlapping full opioid agonist use: the Bernese method. Subst Abus Rehabil. 2016;7:99–105. The first paper to describe the microdosing method of opioid rotation to buprenorphine.CrossRef
61.
Terasaki D, Smith C, Calcaterra SL. Transitioning hospitalized patients with opioid use disorder from methadone to buprenorphine without a period of opioid abstinence using a microdosing protocol. Pharmacotherapy. 2019;39(10):1023–9.PubMedCrossRef
62.
63.
Randhawa PA, Brar R, Nolan S. Buprenorphine-naloxone "microdosing": an alternative induction approach for the treatment of opioid use disorder in the wake of North America's increasingly potent illicit drug market. CMAJ. 2020;192(3):E73.PubMedPubMedCentralCrossRef
64.
De Aquino JP, et al. Rapid transition from methadone to buprenorphine utilizing a micro-dosing protocol in the outpatient veteran affairs setting. J Addict Med. 2020;14(5):e271–3.PubMedPubMedCentralCrossRef
65.
Rozylo J, et al. Case report: successful induction of buprenorphine/naloxone using a microdosing schedule and assertive outreach. Addict Sci Clin Pract. 2020;15(1):2.PubMedPubMedCentralCrossRef
66.
Crane K, et al. Intravenous buprenorphine micro-dosing induction in a patient on methadone treatment: a case report. Psychosomatics. 2020.
67.
• Moe J, et al. Short communication: systematic review on effectiveness of micro-induction approaches to buprenorphine initiation. Addict Behav. 2021;114:106740 A systematic review on effectiveness of microdosing when initiating or opioid rotating to buprenorphine.PubMedCrossRef
68.
69.
Klaire S, et al. Rapid micro-induction of buprenorphine/naloxone for opioid use disorder in an inpatient setting: a case series. Am J Addict. 2019;28(4):262–5.PubMedCrossRef
70.
U.S. Department of Health and Human Services. Pain Management Best Practices Inter-Agency Task Force Report: updates, gaps, inconsistencies, and recommendations. 2019.
71.
Dahan A, et al. Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats. Br J Anaesth. 2005;94(6):825–34.PubMedCrossRef
72.
Yoshikawa A, et al. Opioid use and the risk of falls, fall injuries and fractures among older adults: a systematic review and meta-analysis. J Gerontol Ser A. 2020;75(10):1989–95.CrossRef
73.•
Davis MP. Twelve reasons for considering buprenorphine as a frontline analgesic in the management of pain. J Support Oncol. 2012;10(6):209–19. A user-friendly review that may be used to submit to insurance companies to make the case for them to provide coverage for buprenorphine.PubMedCrossRef
74.••
Pergolizzi J, et al. Opioids and the management of chronic severe pain in the elderly: consensus statement of an international expert panel with focus on the six clinically most often used World Health Organization step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract. 2008;8(4):287–313. A consensus panel that recommends using buprenorphine as first-line opioid analgesic for the elderly.PubMedCrossRef
75.
Giacomuzzi S, et al. Driving impairment on buprenorphine and slow-release oral morphine in drug-dependent patients. Forensic Sci Int. 2005;152(2):323–4.PubMedCrossRef
76.
Kapil RP, et al. Once-weekly transdermal buprenorphine application results in sustained and consistent steady-state plasma levels. J Pain Symptom Manag. 2013;46(1):65–75.CrossRef
77.
Al-Tawil N, et al. Pharmacokinetics of transdermal buprenorphine patch in the elderly. Eur J Clin Pharmacol. 2013;69(2):143–9.PubMedCrossRef
78.
Griessinger N, Sittl R, Likar R. Transdermal buprenorphine in clinical practice--a post-marketing surveillance study in 13,179 patients. Curr Med Res Opin. 2005;21(8):1147–56.PubMedCrossRef
79.
Hirst A, et al. Tramadol and the risk of fracture in an elderly female population: a cost utility assessment with comparison to transdermal buprenorphine. Eur J Health Econ. 2016;17(2):217–27.PubMedCrossRef
80.
Acampora GA, Nisavic M, Zhang Y. Perioperative buprenorphine continuous maintenance and administration simultaneous with full opioid agonist: patient priority at the interface between medical disciplines. J Clin Psychiatry. 2020;81(1).
81.
82.
Greenwald MK, et al. Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers. Neuropsychopharmacology. 2003;28(11):2000–9.PubMedCrossRef
83.
Penza P, et al. Short- and intermediate-term efficacy of buprenorphine TDS in chronic painful neuropathies. J Peripher Nerv Syst. 2008;13(4):283–8.PubMedCrossRef
84.
Walsh SL, et al. Acute administration of buprenorphine in humans: partial agonist and blockade effects. J Pharmacol Exp Ther. 1995;274(1):361–72.PubMed
85.
Metadata
Title
Treating Chronic Pain with Buprenorphine—The Practical Guide
Authors
Amy A. Case
Justin Kullgren
Sidra Anwar
Sandra Pedraza
Mellar P. Davis
Publication date
01-12-2021
Publisher
Springer US
Published in
Current Treatment Options in Oncology / Issue 12/2021
Print ISSN: 1527-2729
Electronic ISSN: 1534-6277
DOI
https://doi.org/10.1007/s11864-021-00910-8

Other articles of this Issue 12/2021

Current Treatment Options in Oncology 12/2021 Go to the issue

Gynecologic Cancers (LA Cantrell, Section Editor)

Options for the Treatment of Mucinous Ovarian Carcinoma

Cardio-oncology (MG Fradley, Section Editor)

The Importance of Primary Care in Cardio-Oncology

Lymphoma (JL Muñoz, Section Editor)

Sequencing of Novel Therapies for Mantle Cell Lymphoma

Sarcoma (SH Okuno, Section Editor)

The Biology of Synovial Sarcoma: State-of-the-Art and Future Perspectives

Lymphoma (JL Muñoz, Section Editor)

Novel Therapies for Follicular Lymphoma and Other Indolent Non-Hodgkin Lymphomas

Neuro-oncology (GJ Lesser, Section Editor)

Role of Laser Interstitial Thermal Therapy in the Management of Primary and Metastatic Brain Tumors
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits